Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases.
Ringdén O, Remberger M, Svenberg P, Svahn BM, Dahllöf G, Gustafsson B, Hassan Z, Omazic B, Uzunel M, Aschan J, Barkholt L, Winiarski J, Ljungman P, Mattsson J. Ringdén O, et al. Among authors: svahn bm. Bone Marrow Transplant. 2007 Apr;39(7):383-8. doi: 10.1038/sj.bmt.1705602. Epub 2007 Feb 19. Bone Marrow Transplant. 2007. PMID: 17310137
A prospective randomized study using N-acetyl-L-cysteine for early liver toxicity after allogeneic hematopoietic stem cell transplantation.
Barkholt L, Remberger M, Hassan Z, Fransson K, Omazic B, Svahn BM, Karlsson H, Brune M, Hassan M, Mattsson J, Ringdén O. Barkholt L, et al. Among authors: svahn bm. Bone Marrow Transplant. 2008 May;41(9):785-90. doi: 10.1038/sj.bmt.1705969. Epub 2008 Jan 7. Bone Marrow Transplant. 2008. PMID: 18176610 Clinical Trial.
BK-viruria and haemorrhagic cystitis are more frequent in allogeneic haematopoietic stem cell transplant patients receiving full conditioning and unrelated-HLA-mismatched grafts.
Giraud G, Priftakis P, Bogdanovic G, Remberger M, Dubrulle M, Hau A, Gutmark R, Mattson J, Svahn BM, Ringden O, Winiarski J, Ljungman P, Dalianis T. Giraud G, et al. Among authors: svahn bm. Bone Marrow Transplant. 2008 Apr;41(8):737-42. doi: 10.1038/sj.bmt.1705962. Epub 2008 Jan 7. Bone Marrow Transplant. 2008. PMID: 18176615
Graft failure in the modern era of allogeneic hematopoietic SCT.
Olsson R, Remberger M, Schaffer M, Berggren DM, Svahn BM, Mattsson J, Ringden O. Olsson R, et al. Among authors: svahn bm. Bone Marrow Transplant. 2013 Apr;48(4):537-43. doi: 10.1038/bmt.2012.239. Epub 2012 Dec 10. Bone Marrow Transplant. 2013. PMID: 23222384 Clinical Trial.
Intraosseous compared to intravenous infusion of allogeneic bone marrow.
Hägglund H, Ringdén O, Agren B, Wennberg L, Remberger M, Rundquist L, Svahn BM, Aspelin P. Hägglund H, et al. Among authors: svahn bm. Bone Marrow Transplant. 1998 Feb;21(4):331-5. doi: 10.1038/sj.bmt.1701116. Bone Marrow Transplant. 1998. PMID: 9509965 Clinical Trial.
Low incidence of acute graft-versus-host disease, using unrelated HLA-A-, HLA-B-, and HLA-DR-compatible donors and conditioning, including anti-T-cell antibodies.
Ringdén O, Remberger M, Carlens S, Hagglund H, Mattsson J, Aschan J, Lönnqvist B, Klaesson S, Winiarski J, Dalianis T, Olerup O, Sparrelid E, Elmhorn-Rosenborg A, Svahn BM, Ljungman P. Ringdén O, et al. Among authors: svahn bm. Transplantation. 1998 Sep 15;66(5):620-5. doi: 10.1097/00007890-199809150-00013. Transplantation. 1998. PMID: 9753343
42 results